永安药业实控人突遭留置 股价7天5个涨停板后为何急转直下

Core Viewpoint - The actual controller and chairman of Yong'an Pharmaceutical, Chen Yong, is under investigation, leading to significant stock price fluctuations and concerns about the company's operational stability [2][5]. Company Overview - Yong'an Pharmaceutical, founded in 2001, specializes in the research, production, and sales of taurine products, health foods, and special dietary foods [8]. - The company is the largest taurine production base globally, with an annual production capacity of 58,000 tons, holding approximately 50% of the market share [8]. - Despite being a major supplier for global brands like Red Bull, Nestlé, and Coca-Cola, the company's revenue has been declining, with reported revenues of 1.462 billion yuan in 2022, 973 million yuan in 2023, and 839 million yuan in 2024 [8]. Recent Developments - Following rumors of a significant price increase in taurine, Yong'an's stock experienced a surge, achieving five consecutive trading limits and a peak increase of nearly 60% within a week [2][6]. - However, the stock has since faced two consecutive trading halts, closing at 10.61 yuan per share on May 9, after the announcement of Chen Yong's investigation [2][6]. Financial Performance - The company's net profit has been under pressure, with a loss of 4.367 million yuan reported in Q1 2025, compared to a profit of 28.68 million yuan in the same period the previous year [8]. - Revenue from taurine accounted for 75.67% of the total revenue, indicating the product's critical role in the company's financial health [8]. Regulatory Environment - The investigation into Chen Yong is part of a broader trend, with multiple company executives facing scrutiny, reflecting tightening regulatory oversight in the capital market [5][6].